Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company

Executive Summary

• Nxera Pharma entered into a license agreement with a newly created independent company (“NewCo”) backed by a leading international life‑sciences investment firm to advance its GPCR‑targeted program.
• The agreement grants Nxera an equity stake in NewCo and rights to receive future milestone payments, royalties, and retain development/commercialization rights for Japan and select Asia‑Pacific territories.
• Nxera may participate in NewCo’s upcoming Series A financing round, potentially bringing additional capital and strategic investors into the partnership.

Key Details

• Agreement Scope: License of Nxera’s GPCR‑targeted asset to NewCo; Nxera retains rights for Japan and certain Asia‑Pacific regions.
• Equity Stake: Nxera receives an undisclosed equity interest in NewCo as part of the transaction.
• Milestones & Royalties: Upon successful development/commercialization, Nxera is entitled to milestone payments and royalties on sales (specific terms confidential).
• Future Financing Participation: Nxera may join NewCo’s Series A financing round alongside major global investment firms.
• Financial Impact: The effect on Nxera’s consolidated results for FY ending 31 Dec 2026 is under review; material disclosures will be made as required.
• Strategic Rationale: Partnership leverages NewCo’s development capability and capital‑raising capacity to maximize the program’s value and patient reach.

Notable Quotes

(No direct quotes were provided in the release.)